Maomeng Tong
Principal
Dr. Maomeng Tong has 15+ years of experience in the healthcare industry across China and the U.S., spanning investment, management consulting, and R&D. At INCE Capital, he focuses on investments in early- to expansion-stage biotech and medtech companies developing cutting-edge, transformative technologies. He has led investments in Allorion Therapeutics, Avenzo Therapeutics, Bambusa Therapeutics, Earendil Labs, and Ronovo Surgical.
Prior to joining INCE, Dr. Tong was with KKR, where he was responsible for investments and operational improvements in its healthcare portfolio. He also worked at McKinsey & Company as a core member of the Greater China Healthcare Practice, advising leading pharmaceutical and medtech companies on strategic and operational initiatives.
Dr. Tong holds a Ph.D. in Medical Pharmacology from the David Geffen School of Medicine at the University of California, Los Angeles, and a B.S. from Tsinghua University.
Prior to joining INCE, Dr. Tong was with KKR, where he was responsible for investments and operational improvements in its healthcare portfolio. He also worked at McKinsey & Company as a core member of the Greater China Healthcare Practice, advising leading pharmaceutical and medtech companies on strategic and operational initiatives.
Dr. Tong holds a Ph.D. in Medical Pharmacology from the David Geffen School of Medicine at the University of California, Los Angeles, and a B.S. from Tsinghua University.